Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fitusiran in Hemophilia A or B with Inhibitors
NCT03417102Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2018
- Primary completion
- Nov 2020
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 17
01
Overview
A Phase 3 trial of fitusiran in hemophilia A, hemophilia B (HB), sponsored by Sanofi. Started Feb 2018; status: completed.
02
Drugs
fitusiran
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT03417102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03417102.